Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-11-02
Ethical does not pass the values gate
Price21.37 USD
Fair value35.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-26Read Accumulation19.87+7.5% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-09-21Read Markdown19.46+9.8% to today Distribution gives way to Markdown after an 18% slide in 4 weeks
2026-08-21Read Distribution23.84-10.4% to today ✓Markdown gives way to Distribution with results news in the headlines
2026-07-02Read Markdown22.86-6.5% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Amentum Holdings, Inc. holds its Accumulation at $21.37. Consolidating, no directional conviction, held for 41 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 41 days
Price at the screen
$21.37
Valuation
26.78 trailing · 8.42 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.16
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
36.36%
Below 33%
Interest-bearing debt is 36.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
25.45%
Below 49%
Money owed to the company is 25.4% of assets, under the 49% limit.
Pass
Revenue purity
0.06%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Amentum Holdings,'s business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AMTM's ethical verdict changes
Today AMTM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 36% discount to our $35.00 fair value.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 38.9% discount to the base estimate.
Where our models see it going: fair-value estimate $35.00, with a range of $35.00 to $44.46, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Government engineering contracts mask stagnant growth
Picture a contractor handling complex US and international projects from digital systems to large scale engineering. The work feels essential yet Amentum shows no revenue growth, a 1% profit margin and just 3% return on equity. Forward earnings sit at 7.5 times but the flat top line and thin returns give little reason to step in despite the ethical screen clearing.
Analysts see value with a 33 dollar median target and our own fair value sits well above the current price. Still the opportunity rating stays at none because low profitability and missing growth outweigh any apparent discount. Unknown competitive position adds another layer of uncertainty around sustained performance.
Risk centres on dependence on government budgets that can shift quickly and the challenge of lifting margins from such low levels. Without visible improvement in returns or scale the setup stays uncompelling even at depressed multiples. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMTM trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-02Accumulation$21.87+10.1%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-10-19Markdown$19.09-1.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-10-12Markdown$19.29+4.4%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-10-02Markdown$18.48-5.0%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-09-21Markdown · changed$19.46-18.4%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 15.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-07-21Markdown$20.68-9.5%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-07-18Markdown$22.86+0.0%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
2026-07-17Markdown$22.86+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it buy, with a mean price target of $34.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
